Product image of Mirabegrón Normon (Mirabegron) supplied by GNH India

Mirabegrón Normon

Active Ingredient:
Mirabegron
Origin:
EU

Mirabegrón Normon (Mirabegron)

Mirabegron, the active ingredient in Mirabegrón Normon, is a β3‑adrenergic receptor agonist presented as an oral dosage form for oral administration. It belongs to the therapeutic class of overactive bladder therapy and is approved in the European Union for treating symptoms such as urinary urgency, frequency, and urge incontinence in adult patients.

GNH India supplies Mirabegrón Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Manufacturer / TM Owner

Laboratorios Normon, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mirabegron is indicated for conditions within the overactive bladder disease spectrum, a disorder characterized by urinary urgency and frequency.

  • Overactive bladder: improves bladder storage capacity, reducing urgency episodes and incontinence.
  • Urinary urgency: lessens the sudden, compelling need to void, helping patients regain control.
  • Urinary frequency: decreases the number of daily voids, improving quality of life.

How It Works

  • Mirabegron selectively activates β3‑adrenergic receptors on detrusor smooth muscle in the bladder. Receptor stimulation raises cyclic AMP levels, causing relaxation of the detrusor during the storage phase, which expands bladder capacity and reduces involuntary contractions. The effect is dose‑dependent and occurs without direct anticholinergic activity, offering an alternative mechanism to traditional bladder antispasmodics.

Side Effects

Mirabegron may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Hypertension: mild to moderate increase in blood pressure.
  • Nasopharyngitis: inflammation of the nasal passages and throat.
  • Urinary tract infection: symptoms such as dysuria or increased frequency.
  • Headache: mild to moderate intensity.
  • Constipation: reduced bowel movements.
  • Dry mouth: sensation of oral dryness.

Serious or Rare Side Effects

  • Urinary retention: difficulty emptying the bladder.
  • Severe hypertension: marked elevation of blood pressure requiring medical attention.
  • Tachycardia: rapid heart rate that may be symptomatic.
  • Angioedema: swelling of the face, lips, or airway.
  • Allergic reactions: rash, pruritus, or anaphylaxis.

Precautions & Warnings

Before initiating Mirabegron therapy, several safety considerations should be reviewed.

  • Monitor blood pressure: check baseline and periodic measurements due to risk of hypertension.
  • Assess renal function: dosage may need adjustment in patients with impaired renal clearance.
  • Review concomitant antihypertensives: potential for reduced efficacy of blood‑pressure‑lowering drugs.
  • Use caution in the elderly: increased susceptibility to cardiovascular effects.
  • Avoid use in uncontrolled hypertension: contraindicated when blood pressure is not adequately controlled.
  • Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Avoid Interactions

Mirabegron can affect the pharmacokinetics of other medicines; interactions are classified by clinical significance.

Major Interactions (Avoid)

  • Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may raise mirabegron plasma levels.
  • MAO inhibitors: combined use may increase risk of hypertensive events.
  • Antihypertensive agents: may diminish blood‑pressure‑lowering effect, requiring close monitoring.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can modestly increase mirabegron exposure.
  • Diuretics: additive effect on blood pressure and electrolyte balance.
  • Anticholinergic drugs: may reduce overall efficacy for bladder symptoms.
  • NSAIDs: potential for increased blood pressure when used together.

Frequently Asked Questions

Mirabegrón Normon contains the active ingredient mirabegron and is prescribed to manage symptoms of overactive bladder, including urinary urgency, increased frequency of urination, and urge incontinence in adult patients.

Mirabegron selectively stimulates β3‑adrenergic receptors on the bladder’s detrusor muscle, raising cyclic AMP levels and causing muscle relaxation during the storage phase. This increases bladder capacity and reduces involuntary contractions that trigger urgency and frequency.

The dose of Mirabegrón Normon is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. The prescriber may start with a low dose and adjust as needed, following local prescribing guidelines.

Safety data for mirabegron in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Mirabegrón Normon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mirabegrón offers a non‑anticholinergic mechanism by targeting β3‑adrenergic receptors, which can be advantageous for patients who experience dry mouth, constipation or cognitive effects from anticholinergics. Both classes improve bladder storage, but individual response and side‑effect profiles differ, so therapy is tailored to each patient.

Mirabegrón tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and keep out of reach of children.

Mirabegrón is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, and the dosing schedule should follow the prescriber’s instructions.

Serious adverse events include marked hypertension, urinary retention, tachycardia, angioedema and severe allergic reactions. Patients should be monitored for rapid blood‑pressure rises, difficulty emptying the bladder, rapid heart rate, facial swelling or signs of anaphylaxis, and seek medical attention promptly if they occur.

Mirabegron should be avoided in patients with uncontrolled hypertension, severe hepatic impairment, known hypersensitivity to mirabegron or any excipients, and in individuals where the risk‑benefit assessment is unfavorable. Clinicians should also exercise caution in patients with significant cardiovascular disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mirabegron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT